Skip to content

PRESS RELEASES


PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Integra LifeSciences Announces Proposed Public Offering of Common Stock
PLAINSBORO, N.J., Nov. 4, 2013 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced that it intends to offer, subject to market conditions and other factors, 3,500,000 shares of its common stock in an underwritten public offering registered under the
View HTML
Toggle Summary Integra LifeSciences Announces Proposed Public Offering of Common Stock
PLAINSBORO, N.J. , May 09, 2018 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation  (NASDAQ:IART), a leading global medical technology company, today announced that it intends to offer, subject to market conditions and other factors, 5,250,000 shares of its common stock in an
View HTML
Toggle Summary Integra LifeSciences Announces Proposed Public Offering of Common Stock
PLAINSBORO, N.J., Aug. 3, 2015 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced that it intends to offer, subject to market conditions and other factors, $200,000,000 of its common stock in an underwritten public offering registered under the Securities
View HTML
Toggle Summary Integra LifeSciences Announces Promotion of Glenn Coleman to Newly-Created Role of Chief Operating Officer and Appointment of Carrie Anderson as Chief Financial Officer
PLAINSBORO, N.J., June 24, 2019 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, today announced the promotion of Glenn Coleman to the newly-created role of chief operating officer (COO) and appointed Carrie Anderson as chief
View HTML
Toggle Summary Integra LifeSciences Announces Preliminary Third Quarter Revenue Results; Will Host Third Quarter 2020 Financial Results Conference Call on October 28, 2020
PRINCETON, N.J., Oct. 06, 2020 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, announced today certain unaudited preliminary third quarter financial results. The company also announced that it will release full third quarter
View HTML
Toggle Summary Integra LifeSciences Announces Preliminary Second Quarter Revenue Results; Will Host Second Quarter 2020 Financial Results Conference Call on August 10, 2020
PRINCETON, N.J., July 09, 2020 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, announced today certain unaudited preliminary second quarter financial results. The company also announced that it will release full second
View HTML
Toggle Summary Integra LifeSciences Announces Preliminary Fourth Quarter and Full-Year 2020 Revenue Results; Will Host Fourth Quarter Financial Results Conference Call on February 18, 2021
PRINCETON, N.J., Jan. 14, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, announced today certain unaudited preliminary fourth quarter and full-year 2020 revenue results. Preliminary Fourth Quarter and Full-Year 2020
View HTML
Toggle Summary Integra LifeSciences Announces Preliminary Fourth Quarter and Full-Year 2019 Revenue Results and 2020 Financial Guidance
Fourth quarter 2019 reported revenue is expected to be at or near the low end of the previously communicated guidance range of $395 to $400 million, representing organic revenue growth of slightly less than 5% and reported growth of approximately 3%; For the full-year 2020, the company is providing
View HTML
Toggle Summary Integra LifeSciences Announces Preliminary Fourth Quarter 2018 Financial Results
Preliminary Fourth Quarter 2018 Highlights: Fourth quarter 2018 reported revenue is expected to be at the higher end of the company’s previous guidance range of $378 million to $383 million; Organic revenue growth in the fourth quarter 2018 is expected to be slightly above 4%.
View HTML
Toggle Summary Integra LifeSciences Announces Preliminary Fourth Quarter 2017 Financial Results
Preliminary Fourth Quarter Highlights: Fourth quarter 2017 reported revenue is expected to be approximately $365 million, exceeding the high-end of the company's previous implied guidance range of $345 million to $355 million; Organic revenue growth in the fourth quarter is expected to be about
View HTML
Toggle Summary Integra LifeSciences Announces Preliminary First Quarter Revenue Results and Provides an Update on COVID-19 Impact; Will Host First Quarter 2020 Financial Results Conference Call on May 7, 2020
PRINCETON, N.J., April 07, 2020 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, announced today certain unaudited preliminary first quarter financial results.  The company also announced that it will release full first
View HTML
Toggle Summary Integra LifeSciences Announces Poster Presentation 'Periradicular Lumbar Fibrosis: What to Do?' At 2007 Congress of Neurological Surgeons Annual Meeting
PLAINSBORO, N.J., Sep 17, 2007 (PrimeNewswire via COMTEX News Network) -- Integra LifeSciences Holding Corporation (Nasdaq:IART) is pleased to announce the poster presentation "Periradicular Lumbar Fibrosis: What to Do?" by Dr. Inaki Arrotegui, of the Department of Neurosurgery, University of
View HTML
Toggle Summary Integra LifeSciences Announces Positive Clinical Results for Integra® Bilayer Wound Matrix (IBWM)
Data Shows IBWM Reduced Operating Room Time and Costs Associated with Lower Extremity Wounds PRINCETON, N.J., May 15, 2020 (GLOBE NEWSWIRE) -- Integra LifeSciences Holding Corporation (Nasdaq: IART), a leading global medical technology company, today announced positive clinical and economic data on
View HTML
Toggle Summary Integra LifeSciences Announces Positive Clinical Outcomes for PriMatrix® Dermal Repair Scaffold for the Management of Diabetic Foot Ulcers
Data Shows a Single Application of PriMatrix Closed More Wounds Than Standard of Care Alone PRINCETON, N.J., July 19, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holding Corporation (Nasdaq: IART), a leading global medical technology company, today announced positive clinical outcomes for
View HTML
Toggle Summary Integra LifeSciences Announces Positive Clinical and Economic Outcomes for Codman® Bactiseal® EVD Catheter from a Real-World Evidence Study
Data Shows Codman Bactiseal EVD Catheter Reduced Hospital Stay and Costs Associated with Hemorrhagic Stroke Patients PRINCETON, N.J., July 6, 2023 -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, today announced positive clinical and economic
View HTML